Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial

Published:2016-05-26 Issue:6 Volume:68 Page:744-752
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Emery Paul¹,Fleischmann Roy M.²,Strusberg Ingrid³,Durez Patrick⁴,Nash Peter⁵,Amante Eric Jason B.⁶,Churchill Melvin⁷,Park Won⁸,Pons‐Estel Bernardo⁹,Han Chenglong¹⁰,Gathany Timothy A.¹⁰,Xu Stephen¹¹,Zhou Yiying¹¹,Leu Jocelyn H.¹¹,Hsia Elizabeth C.¹²

Affiliation:

1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Hospitals NHS TrustLeeds UK

2. University of Texas and Southwest Medical CenterDallas Texas

3. Instituto Reumatológico StrusbergCórdoba Argentina

4. Service et Pôle de Rhumatologie, Cliniques Universitaires Saint‐Luc, and Institut de Recherche Expérimentale et Clinique, Université Catholique de LouvainBrussels Belgium

5. University of QueenslandQueensland Australia

6. University of the Philippines General HospitalManila Philippines

7. Arthritis Center of NebraskaLincoln

8. Inha University HospitalIncheon South Korea

9. Sanatorio ParqueSanta Fe Argentina

10. Janssen Global Services, LLCMalvern Pennsylvania

11. Janssen Research & DevelopmentSpring House Pennsylvania

12. Janssen Research & Development, Spring House, Pennsylvania, and University of Pennsylvania School of MedicinePhiladelphia

Funder

Janssen Research & Development, LLC.

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.22759

Reference24 articles.

1. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

2. Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

3. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

4. Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1-Year and 2-Year Clinical, Radiologic, and Physical Function Findings

5. The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis;Clinical Rheumatology;2023-09-26

2. Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis;Musculoskeletal Care;2022-08-22

3. Assessment of Rheumatoid Hand Function as a Characteristic Feature of Rheumatoid Arthritis in Patients Treated with Methotrexate or Methotrexate with Biological Agents with or without Deformation of Hands;Current Rheumatology Reviews;2022-08

4. POS0947 LONG-TERM GOLIMUMAB PERSISTENCE: 5-YEAR TREATMENT RETENTION DATA POOLED FROM FIVE PHASE III CLINICAL TRIALS IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS;Annals of the Rheumatic Diseases;2022-05-23

5. Toward Overcoming Treatment Failure in Rheumatoid Arthritis;Frontiers in Immunology;2021-12-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3